Huntington's Disease

ABSTRACT

Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment. It is an autosomal-dominant disorder that has a substantial impact on family structure and dynamics in terms of providing care for affected family members and, for the offspring of an affected parent, dealing with at-risk status. Therapy that slows the progressive neuronal dysfunction or degeneration is unavailable, so pharmacotherapy is currently aimed primarily at managing behavioral and psychiatric symptoms, and, in selected cases, controlling severe chorea. Effective intervention by clinicians is possible, however, in terms of providing patients and families with accurate information about the disease, counseling them about availability of genetic testing at specialized centers, and in giving them sound advice regarding work, driving, relationships, finances, research participation, and support groups.

KEYWORDS

Huntington's disease - genetic testing - CAG repeat disorders - chorea - movement disorders - subcortical dementia

REFERENCES

• 1 Rubinsztein D C, Leggo J, Coles R et al.. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats.  Am J Hum Genet. 1996;  59 16-22
• 2 Ranen N G, Stine O C, Abbott M H et al.. Anticipation and instability of IT-15(CAG)n repeats in parent-offspring pairs with Huntington's disease.  Am J Hum Genet. 1995;  57 593-602
• 3 Kremer B, Almqvist E, Theilmann J et al.. Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes.  Am J Hum Genet. 1995;  57 343-350
• 4 Andrew S E, Goldberg Y P, Kremer B et al.. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.  Nat Genet. 1993;  4 398-403
• 5 The Huntington's Disease Collaborative Research Group . A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.  Cell. 1993;  72 971-983
• 6 Wexler N S, Lorimer J, Porter J et al.. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.  Proc Natl Acad Sci USA. 2004;  101 3498-3503
• 7 Harper P S, Jones L. Huntington's disease: genetic and molecular studies. In: Bates G, Harper P, Jones L Huntington's Disease. New York; Oxford University Press 2002: 113-158
• 8 Rubinsztein D C. Molecular biology of Huntington's disease (HD) and HD-like disorders. In: Pulst S Genetics of Movement Disorders. San Diego; Academic Press 2003: 365-377
• 9 Takano H, Cancel G, Ikeuchi T et al.. Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations.  Am J Hum Genet. 1998;  63 1060-1066
• 10 Pridmore S A. The large Huntington's disease family of Tasmania.  Med J Aust. 1990;  153 593-595
• 11 The World Federation of Neurology Research Group on Huntington's Disease . Presymptomatic testing for Huntington's disease: a world-wide survey.  J Med Genet. 1993;  30 1020-1022
• 12 Creighton S, Almqvist E W, MacGregor D et al.. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987-2000.  Clin Genet. 2003;  63 462-475
• 13 Timman R, Roos R, Maat-Kievit A, Tibben A. Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test.  Health Psychol. 2004;  23 189-197
• 14 Almqvist E W, Brinkman R R, Wiggins S, Hayden M R. Canadian Collaborative Study of Predictive Testing . Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease.  Clin Genet. 2003;  64 300-309
• 15 International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea . Guidelines for the molecular genetics predictive test in Huntington's disease.  Neurology. 1994;  44 1533-1536
• 16 Gutekunst C, Norflus F, Hersch S. The neuropathology of Huntington's disease. In: Bates G, Harper P, Jones L Huntington's Disease. New York; Oxford University Press 2002: 251-275
• 17 Graham R K, Deng Y, Slow E G et al.. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.  Cell. 2006;  125 1179-1191
• 18 Wanker E, Droge A. Structural biology of Huntington's disease. In: Bates G, Harper P, Jones L Huntington's Disease. New York; Oxford University Press 2002: 327-347
• 19 Panov A V, Burke J R, Strittmatter W J, Greenamyre J T. In vitro effects of polyglutamine tracts on a Ca2 + dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.  Arch Biochem Biophys. 2003;  410 1-6
• 20 Charrin B C, Saudou F, Humbert S. Axonal transport failure in neurogenerative disorders: the case of Huntington's disease.  Pathol Biol. 2005;  53 189-192
• 21 Cha J H. Transcriptional dysregulation in Huntington's disease.  Trends Neurosci. 2000;  23 387-392
• 22 Rangone H, Humbert S, Saudou F. Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?.  Pathol Biol. 2004;  52 338-342
• 23 Duan W, Guo Z, Jiang H et al.. Paroxetine retards disease onset and progression in Huntingtin mutant mice.  Ann Neurol. 2004;  55 590-594
• 24 Bae B I, Xu H, Igarashi S et al.. P53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease.  Neuron. 2005;  47 29-41
• 25 Freeman W, Morton A J. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.  Brain Res Bull. 2004;  63 45-55
• 26 Hickey M A, Chesselet M F. Apoptosis in Huntington's disease.  Prog Neuropsychopharmacol Biol Psychiatry. 2003;  27 255-265
• 27 Higgins Jr D S. Huntington's disease.  Curr Treat Options Neurol. 2006;  8 236-244
• 28 Yamamoto A, Lucas J J, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease.  Cell. 2000;  101 57-66
• 29 Montoya A, Price B H, Menear M, Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease.  J Psychiatry Neurosci. 2006;  31 21-29
• 30 Paulsen J S, Conybeare R A. Cognitive changes in Huntington's disease.  Adv Neurol. 2005;  96 209-225
• 31 Anderson K E, Marshall F J. Behavioral symptoms associated with Huntington's disease.  Adv Neurol. 2005;  96 197-208
• 32 Snowden J S, Craufurd D, Griffiths H L, Neary D. Awareness of involuntary movements in Huntington disease.  Arch Neurol. 1998;  55 801-805
• 33 Blekher T, Johnson S A, Marshall J et al.. Saccades in presymptomatic and early stages of Huntington disease.  Neurology. 2006;  67 394-399
• 34 Nance M A. The US Huntington Disease Genetic Testing Group. Genetic testing of children at risk for Huntington's disease.  Neurology. 1997;  49 1048-1053
• 35 Walker F O. Cultivating simple virtues in medicine.  Neurology. 2005;  65 1678-1680
• 36 Rebok G W, Bylsma F W, Keyl P M, Brandt J, Folstein S E. Automobile driving in Huntington's disease.  Mov Disord. 1995;  10 778-787
• 37 Beglinger L J, Langbehn D R, Duff K et al.. Probability of obsessive and compulsive symptoms in Huntington's disease.  Biol Psychiatry. 2006; July 11 ;  , (Epub ahead of print)
• 38 Mahant N, McCusker E A, Byth K, Graham S. Huntington Study Group. Huntington's disease: clinical correlates of disability and progression.  Neurology. 2003;  61 1085-1092
• 39 Hunt V P, Walker F O. Dysphagia in Huntington's disease.  J Neurosci Nurs. 1989;  21 92-95
• 40 Moskowitz C B, Marder K. Palliative care for people with late-stage Huntington's disease.  Neurol Clin. 2001;  19 849-865
• 41 Walker F O. Huntington's disease.  Lancet. 2007;  369 218-228
• 42 Bonelli R M, Wenning G K. Pharmacological management of Huntington's disease: an evidence-based review.  Curr Pharm Des. 2006;  12 2701-2720
• 43 Arciniegas D B, Anderson C A. Suicide in neurologic illness.  Curr Treat Options Neurol. 2002;  4 457-468